Epeius Biotechnologies' lead product, Rexin-G, has been granted Fast Track designation by the FDA for use as a second-line treatment for advanced or metastatic pancreatic cancer. The drug is currently in Phase II trials. Release
Epeius Biotechnologies' lead product, Rexin-G, has been granted Fast Track designation by the FDA for use as a second-line treatment for advanced or metastatic pancreatic cancer. The drug is currently in Phase II trials. Release